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The mammalian target of rapamycin (mTOR) interacts with raptor to form the protein complex mTORC1
(mTOR complex 1), which plays a central role in the regulation of cell growth in response to environmental
cues. Given that glucose is a primary fuel source and a biosynthetic precursor, how mTORC1 signaling is
coordinated with glucose metabolism has been an important question. Here, we found that the glycolytic
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) binds Rheb and inhibits mTORC1 signaling.
Under low-glucose conditions, GAPDH prevents Rheb from binding to mTOR and thereby inhibits mTORC1
signaling. High glycolytic flux suppresses the interaction between GAPDH and Rheb and thus allows Rheb to
activate mTORC1. Silencing of GAPDH or blocking of the Rheb-GAPDH interaction desensitizes mTORC1
signaling to changes in the level of glucose. The GAPDH-dependent regulation of mTORC1 in response to
glucose availability occurred even in TSC1-deficient cells and AMPK-silenced cells, supporting the idea that
the GAPDH-Rheb pathway functions independently of the AMPK axis. Furthermore, we show that glyceral-
dehyde-3-phosphate, a glycolytic intermediate that binds GAPDH, destabilizes the Rheb-GAPDH interaction
even under low-glucose conditions, explaining how high-glucose flux suppresses the interaction and activates
mTORC1 signaling. Taken together, our results suggest that the glycolytic flux regulates mTOR’s access to
Rheb by regulating the Rheb-GAPDH interaction, thereby allowing mTORC1 to coordinate cell growth with
glucose availability.
The mTOR complex 1 (mTORC1) signal transduction path-
way acts as a central controller of cell growth in mammals (20,
23, 29). mTORC1 integrates a wide range of intracellular and
extracellular signals, including insulin, availability of nutrients
(glucose and amino acids), cellular energy status, and hypoxia,
to regulate protein synthesis and cell growth (11, 12, 17, 36,
46). Many of these environmental cues are integrated into
tuberous sclerosis complex (TSC1-TSC2), the major upstream
regulator of mTORC1. In response to the absence of insulin
and to the low-energy status of cells, the TSC1-TSC2 complex
stimulates the GTPase function of Rheb, a small GTPase that
acts as a proximal key activator of mTORC1, which leads to
the inhibition of Rheb-mediated mTORC1 activation. In con-
trast, inactivation of the TSC1-TSC2 complex results in the
accumulation of GTP-bound Rheb and thus activation of
mTORC1 (3, 13, 21, 27, 32, 39). For this reason, both the loss
of TSC proteins and the overexpression of Rheb cause hyper-
activation of mTORC1 signaling, which is frequently observed
in many common human cancers (2, 5, 19, 25, 33). Therefore,
a tight regulation of Rheb activity is critical for the proper
operation of the mTORC1 pathway in response to environ-
mental cues.
Rheb is an atypical member of the Ras superfamily of
GTPases (1, 10, 47). As with other small GTPases, the activity of
Rheb is regulated by its guanine nucleotide binding status.
However, the negative control of GTP-bound Rheb by the
TSC1-TSC2 complex has only recently been investigated, and
the regulation of the nucleotide binding status of Rheb is
not fully understood. A recent study proposed that transla-
tionally controlled tumor protein may function as a guanine
nucleotide exchange factor for Rheb that causes the accu-
mulation of GTP-bound Rheb (18). GTP-bound Rheb is
essential for activating mTOR kinase (21, 28, 38). However,
the interaction between Rheb and mTOR does not depend
on the GTP binding status of Rheb (30), raising questions
regarding the mechanism by which Rheb activates mTORC1.
Recently, FKBP38 (immunophilin FK506-binding protein, 38
kDa) was found to be a direct binding partner of Rheb and an
inhibitor of mTORC1 (4). GTP-bound Rheb binds FKBP38
and releases FKBP38 from mTORC1, resulting in activation of
the mTORC1 pathway. However, there have been conflicting
results regarding the effects of nutrient availability on Rheb
activity (31, 37, 42, 50) and the effect of these newly identified
regulators of Rheb function (44, 45). Thus, the precise molec-
ular mechanisms underlying Rheb regulation and Rheb-medi-
ated mTORC1 activation have remained unclear.
In this study, we identified glyceraldehyde-3-phosphate (Gly-
3-P) dehydrogenase (GAPDH) as a novel Rheb binding protein
and a negative regulator of Rheb. We found that the interaction
between GAPDH and Rheb is induced when the glycolytic flux is
suppressed under low-glucose conditions to inhibit mTORC1.
Here, we provide a molecular mechanism underlying the cross
talk between the glycolytic flux and the mTORC1 signaling.
* Corresponding author. Mailing address: Division of Molecular
and Life Sciences, Pohang University of Science and Technology
(POSTECH), Pohang, Kyungbook 790-784, South Korea. Phone: 82-
54-279-2292. Fax: 82-54-279-0645. E-mail: sungho@postech.ac.kr.
 Published ahead of print on 18 May 2009.
3991
 o
n
 Septem
ber 3, 2014 by ULSAN NATIO
NAL INS O
F SCIENCE & TECHNO
LO
G
Y(UNIST)
http://m
cb.asm
.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Cell culture, transfection, and sample preparation. HEK293, TSC1/, and
TSC1/ mouse embryo fibroblasts (MEFs) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Cambrex) containing 10% fetal bovine
serum (Cambrex). Transfection was performed using Lipofectamine reagent
(Invitrogen), according to the manufacturer’s instructions. For RNA interfer-
ence experiments, the medium for cells was supplemented with 1 mM sodium
pyruvate, and cells were transfected with 100 nM of GAPDH (Bionner and
GenePharma), AMPK1 (siGENOME SMARTpool M-005027-02-0005; Dhar-
macon), or control luciferase small interfering RNA (siRNA) (Dharmacon)
using Lipofectamine reagent. Target sequences for human GAPDH_#1 and
GAPDH_#2 were 5-GTGTGACCATGAGAAGTA-3 and 5-GTATGACAA
CAGCCTCAAGTT-3, respectively. To deprive cells of glucose, cells were
starved in serum-free DMEM for 1 h and then incubated in low-glucose DMEM
containing 5 mg/ml D-glucose (Gibco BRL). To resupply cells with normal
glucose, the medium was replaced with serum-free DMEM containing 25 mg/ml
D-glucose (Gibco BRL). After treatment, cells were washed twice with phos-
phate-buffered saline and then harvested with CHAPS lysis buffer (40 mM
HEPES, pH 7.5, 0.5% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesul-
fonate [CHAPS], 120 mM NaCl, 1 mM EDTA, 10 mM pyrophosphate, 50 mM
NaF, 1.5 mM Na2VO3, 10 mM -glycerophosphate, 1 mM phenylmethylsulfonyl
fluoride [PMSF], 10 mM MgCl2, and 10 g/ml leupeptin). The cell extracts
generated were spun at 14,000 rpm for 15 min and then stored at 80°C.
Chemicals and materials. All chemicals were purchased from Sigma unless
stated otherwise. Anti-Myc 9E10 and antihemagglutinin (anti-HA) 12CA5 were
harvested from the supernatants of corresponding hybridoma cell lines. Anti-
Rheb (C19) antibodies were purchased from Santa Cruz, and anti-mTOR, Rheb,
Raptor, pS6K1 (pThr389), S6K1, p4EBP1 (pThr37/46), 4EBP1, TSC1, pAMPK
(pThr147), pERK (pThr202/Tyr204), extracellular signal-regulated kinase,
pAKT (Ser473), AKT, ACC antibodies, and rapamycin were from Cell Signaling.
Anti-GAPDH monoclonal antibodies were purchased from Biogenesis (King-
stone, NH), and pACC (Ser79) antibodies were purchased from Upstate Bio-
technology. Compound C was obtained from Merck. Protein A-Sepharose and
protein G-Sepharose beads were from RepliGen (Needham, MA) and Pierce,
respectively. Horseradish peroxidase-conjugated goat anti-mouse immuno-
globulin A (IgA)-IgM-IgG, peroxidase-conjugated goat anti-rabbit IgG, and
peroxidase-conjugated rabbit anti-goat IgG antibodies were purchased from
Kirkegaard and Perry Laboratories (Gaithersburg, MD). The enhanced
chemiluminescence kit was purchased from Amersham Biosciences Interna-
tional (Buckinghamshire, United Kingdom).
Identification of Rheb binding proteins. Rat brains were homogenized in lysis
buffer (20 mM Tris-HCl, pH 7.8, 150 mM NaCl, 1 mM MgCl2, 1 mM EGTA, 1%
Triton X-100) and cleared by centrifugation for 15 min at 14,000 rpm. Superna-
tants were spun at 67,000 rpm for 30 min, and brain extracts were incubated with
immobilized glutathione S-transferase (GST)-tagged Rheb proteins for 2 h at
4°C. Proteins unique to Rheb were excised from the gel and digested with
trypsin. Tryptic peptides were analyzed with a 4700 proteomics analyzer (Applied
Biosystems, Framingham, MA). The measured spectrum was analyzed using an
in-house version of Mascot (version 2.0) for peptide mass fingerprinting. The
NCBInr database was used, and the Mascot score for a significant hit (P  0.05)
was greater than 67.
Plasmids. HA-tagged Rheb clones and pGEX-2T-RhebWT were kindly pro-
vided by Ariel F. Castro (Indiana University School of Medicine), and Myc-
mTOR was kindly provided by David M. Sabatini (Massachusetts Institute of
Technology). Full-length Rheb cDNA obtained by PCR was subcloned into
pEGFP-C1 (BD Biosciences) and pRSETB (Invitrogen) with an N-terminal
green fluorescent protein (GFP) tag or His tag, respectively. To generate the
GST-tagged Rheb fragment, the fragment of rat Rheb cDNA obtained by PCR
was cloned into pGEX-4T-1 (Amersham Pharmacia Biotech). cDNAs encoding
human GAPDH were obtained by PCR and subcloned into N-terminal pFLAG-
CMV (Sigma).
Immunoprecipitation. For immunoprecipitation, 0.5- to 1-mg aliquots of cell
extracts were incubated with 2 g of the indicated antibodies for 6 h at 4°C under
gentle agitation. Immunocomplexes were collected with protein A- (RepliGen)
or protein G-Sepharose beads (Pierce). Whole-cell lysates or immunoprecipi-
tates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and immunoblotting. All immunoblots were detected by en-
hanced chemiluminescence (ECL system; Amersham).
In vitro binding assay. GST-tagged Rheb proteins were immobilized on glu-
tathione-Sepharose beads (GE Healthcare) and resuspended in binding buffer
(40 mM HEPES, pH 7.5, 0.5% Triton X-100, 120 mM NaCl, 1 mM EDTA, 1 mM
PMSF, and 10 mM MgCl2). To obtain soluble proteins, GST-tagged GBR was
eluted off the beads with 50 mM glutathione in 50 mM Tris-HCl (pH 7.5). To
prepare His-tagged Rheb proteins, cell lysates were incubated with nickel-ni-
trilotriacetic acid (Ni-NTA) agarose beads (Qiagen) and washed with buffer
containing 20 mM, 50 mM, and 100 mM imidazole, in sequence. The beads were
subsequently resuspended in binding buffer. For charging GST-Rheb with nu-
cleotides in vitro, immobilized GST or GST-Rheb was washed with nucleotide-
free buffer (50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 0.5% Triton X-100, 1 mM
dithiothreitol, 1 mM PMSF, and 20 mM EDTA). Beads were washed with
loading buffer (40 mM HEPES, pH 7.5, 120 mM NaCl, 5 mM EDTA, and 2 mM
MgCl2) and nucleotide preloaded with 200 l of loading buffer containing 100
M GDPS or 100 M GTPS for 1 h at 4°C, and the process was then
terminated by adding 5 l of 1 M MgCl2. For nucleotide-free Rheb, beads were
resuspended in nucleotide-free buffer. A 50 nM concentration of purified rabbit
muscle GAPDH (Sigma) was incubated with 1 g of immobilized GST-Rheb on
glutathione-Sepharose or GST-glutathione-Sepharose for 2 h at 4°C in binding
buffer. For in vitro competitive assays using GST-tagged GBR, GAPDH was
mixed with immobilized His-tagged full-length Rheb on Ni-NTA agarose. Puri-
fied GST-GBR was then added in increasing amounts (0, 1, and 5 g) and
incubated for 2 h at 4°C.
RESULTS
Glycolytic flux regulates the interaction between Rheb and
GAPDH. To gain a clearer understanding of the mechanisms
that regulate Rheb GTPase, we sought to identify Rheb-inter-
acting proteins. GST-tagged Rheb was incubated with rat brain
extracts, and proteins specifically bound to GST-Rheb were
resolved by SDS-PAGE and identified by mass spectrometry.
One of the proteins identified was GAPDH, a glycolytic en-
zyme that converts Gly-3-P to 1,3-bisphosphoglycerate (Fig.
1A to C). Because GAPDH is a highly abundant protein, we
analyzed the specificity of the interaction by using several con-
trol proteins and antibodies. We purified GST-tagged Rheb
and other small GTPases from Escherichia coli and incubated
them with purified GAPDH in vitro. Supporting the specificity
of the Rheb-GAPDH interaction, GAPDH precipitated with
Rheb but not with the other small GTPases (Fig. 1D). To
confirm the interaction between GAPDH and Rheb in intact
cells, we examined the association between transfected HA-
Rheb and Flag-GAPDH in HEK293 cells. We found that im-
munoprecipitation with either Flag or HA antibodies revealed
a specific interaction between Rheb and GAPDH (Fig. 1E).
Next, we tested whether endogenous GAPDH interacts with
endogenous Rheb. Immunoprecipitates obtained using an an-
tibody specific to Rheb, but not control antibodies, contained
endogenous GAPDH (Fig. 1F).
To further confirm the interaction between GAPDH and
Rheb, we asked whether the interaction might be regulated by
the state of the cell. First, we tested whether the interaction is
regulated by the GTP-GDP-bound state of Rheb. The binding
of GAPDH to Rheb did not depend on the guanyl nucleotide
charge status of Rheb (Fig. 2A), indicating that GAPDH is
unlikely to be either a guanine nucleotide exchange factor or a
GTPase-activating protein. Next, we tested whether the inter-
action is regulated by glucose availability. Given that GAPDH
is involved in glucose metabolism (8, 16) and that the
GAPDH-mediated reaction is determined by extracellular glu-
cose availability (6, 43), we reasoned that glucose availability
might regulate the interaction of GAPDH to Rheb. The bind-
ing of endogenous GAPDH to Rheb was strongly enhanced in
the absence of glucose, and this binding gradually decreased as
extracellular glucose levels were elevated (Fig. 2B). The
binding of Rheb to GAPDH was increased within 15 min of
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FIG. 1. Identification of p38 as GAPDH. (A) Identification of GAPDH as a Rheb-associated protein. Precipitates of GST-Rheb from rat
brain extracts were separated by SDS-PAGE and stained with Coomassie blue. The 38-kDa band was identified as GAPDH. (B) In-gel
digestion and mass spectrometry analysis were done for identification of p38. Peptide mass fingerprinting showed that eight peptides were
matched to the deduced sequence of a rat protein in the database, GAPDH. Matched peaks in the spectrum are indicated by arrowheads,
and amino acid sequences of rat GAPDH are shown. Matched peptide sequences are shown by underlining. (C) Confirmation of
identification of GAPDH as Rheb-associated protein. Precipitates of GST-Rheb from rat brain extracts were separated by SDS-PAGE and
immunoblotted with anti-GAPDH antibodies. The GST immunoblot shows the relative amounts of GST proteins used. (D) GAPDH directly
interacts with Rheb but not other small GTPases. GST, GST-Rheb, GST-RhoA, GST-Rac1, or GST-Cdc42 was incubated with purified
rabbit muscle GAPDH. After GST pulldown assays were performed, bound GAPDH was analyzed by immunoblotting with anti-GAPDH
antibodies (upper panel). The amounts of GST-small GTPases used were shown by Ponceau S staining (lower panel). (E) Coimmunopre-
cipitation of GAPDH and Rheb in intact cells. HEK293 cells were transfected with either HA-Rheb or Flag-tagged GAPDH alone or
together with both. Cell lysates were immunoprecipitated with anti-HA antibodies or anti-Flag antibodies and then analyzed by Western
blotting with indicated antibodies. (F) Confirmation of the interaction between endogenous GAPDH and Rheb. Immunoprecipitates were
isolated from HEK293 cells by using Rheb-specific or control antibodies (anti-aryl hydrocarbon receptor [AhR] antibody and control goat
IgG antibody). The amount of GAPDH isolated with Rheb was detected by immunoblotting with anti-GAPDH antibody.
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switching cells to low-glucose-containing medium (Fig. 2C).
Moreover, treatment with the glucose analog 2-deoxyglu-
cose (2DG), which inhibits glycolysis (7), strongly induced the
interaction between Rheb and GAPDH (Fig. 2C). We con-
firmed that low-glucose conditions induce the binding of
GAPDH to Rheb but not to other small GTPases such as
H-Ras and Rap2A (Fig. 2D). These results support the idea
that GAPDH specifically interacts with Rheb and that the
glycolytic flux regulates the Rheb-GAPDH interaction.
Gly-3-P, an intermediate of the glycolytic pathway, destabi-
lizes the interaction between GAPDH and Rheb. Knowing that
glycolytic flux regulates the GAPDH-Rheb interaction, we
wondered whether any glycolytic metabolite might regulate
this interaction. GAPDH converts Gly-3-P to 1,3-bisphospho-
glycerate while reducing NAD to NADH (16, 35, 49). There-
fore, we asked whether any of the metabolites capable of
binding GAPDH might regulate the interaction between
GAPDH and Rheb. Neither NAD nor NADH had any effect
on the Rheb-GAPDH interaction, but Gly-3-P showed an in-
hibitory effect on the interaction (Fig. 3A). We also tested
other glycolytic metabolites such as glucose, dihydroxyacetone
phosphate, and 3-phosphoglycerate (3-PG) without seeing any
significant effects on the interaction (Fig. 3B). Furthermore,
we found that the Rheb-GAPDH interaction under low-glu-
cose conditions was reduced by Gly-3-P in a dose-dependent
manner (Fig. 3C). In contrast, 3-PG (which is both a structural
analog and a metabolic product of Gly-3-P) had no effect on
the Rheb-GAPDH interaction (Fig. 3D). These results suggest
that the GAPDH-Rheb interaction is negatively regulated by
the binding of the glycolytic pathway intermediate Gly-3-P to
GAPDH.
GAPDH negatively regulates mTORC1. Knowing that
GAPDH interacts with Rheb and that the interaction is regu-
lated by the glycolytic pathway, we next asked whether this
interaction affects the activity of mTORC1. We first analyzed
the effect of GAPDH knockdown on the activity of mTORC1
by examining the phosphorylation states of S6K1 and 4EBP1.
For this experiment, cells were supplemented with 1 mM so-
dium pyruvate to prevent cell death due to metabolic defects
(15, 51). Knockdown of GAPDH using two distinct nonover-
lapping siRNAs against GAPDH increased the phosphoryla-
tion states of both S6K1 and 4EBP1 but had no effect on other
signaling molecules such as AKT, extracellular signal-regu-
lated kinase, and ACC (Fig. 4A), indicating that GAPDH
specifically regulates the mTORC1 pathway. The phosphory-
lation level inversely correlated with the amount of GAPDH
remaining in the cell (Fig. 4A). This result indicates that
GAPDH basally modulates mTORC1 activity under normal
growth condition (25 mM glucose). We next tested the effect of
GAPDH silencing under low-glucose conditions (5.5 mM glu-
cose). HEK293 cells transfected with either control luciferase
siRNA or GAPDH siRNA were cultured in low- and high-
glucose medium, and the phosphorylation state of S6K1 was
analyzed. Knockdown of GAPDH increased the basal phos-
phorylation of S6K1 under the high-glucose condition (as in
Fig. 4A), and it significantly suppressed the inhibitory effects of
low glucose levels on S6K1 phosphorylation (Fig. 4B). This
FIG. 2. GAPDH interacts with Rheb, and the interaction is regulated by glycolytic flux. (A) The interaction of Rheb with GAPDH does not
depend on its nucleotide binding status. GST or GST-Rheb was charged with 100 M GDPS or 100 M GTPS. Each species of GST or
GST-Rheb was incubated with purified rabbit muscle GAPDH. After GST pulldown assays were performed, bound GAPDH was analyzed by
immunoblotting with anti-GAPDH antibodies (upper panel). The amount of GST-Rheb used was shown by Ponceau S staining (lower panel).
(B) Interaction between Rheb and GAPDH is regulated by extracellular glucose availability. HEK293 cells were incubated in media containing
the indicated concentrations of glucose for 30 min. Lysates prepared from these cells were immunoprecipitated with anti-Rheb antibodies.
GAPDH bound to Rheb was analyzed by anti-GAPDH immunoblotting. (C) The inhibition of glycolytic flux induces Rheb-GAPDH interaction.
HEK293 cells were treated with 25 mM 2DG or incubated in 5.5 mM glucose medium for the indicated times. Lysates prepared from these cells
were immunoprecipitated with anti-Rheb antibodies. GAPDH bound to Rheb was analyzed by anti-GAPDH immunoblotting. (D) GAPDH
specifically interacts with Rheb but not other Ras GTPases. HEK293 cells were transfected with wild-type HA-Rheb, HA–H-Ras, or HA-Rap2A
and incubated in media containing the indicated concentration of glucose for 30 min. Lysates prepared from these cells were immunoprecipitated
with anti-HA antibodies. GAPDH bound to Rheb was analyzed by anti-GAPDH immunoblotting.
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result supports the idea that GAPDH is important for the
glucose-responsive regulation of mTORC1 activity.
Glucose availability has been known to regulate mTORC1
via the AMPK-TSC pathway and AMPK-mediated phosphory-
lation of raptor (14, 22). Our findings suggest that a novel
additional signaling axis regulates mTORC1 in response to
glucose availability. Supporting the idea that the AMPK-TSC
axis is not the sole glucose-responsive pathway of mTORC1
activation, mTORC1 activity was still inhibited by glucose de-
privation and 2DG in both TSC1-deficient MEFs and TSC1/
wild-type (WT) cells (Fig. 4C and D). In addition, incubation
of cells with 2DG suppressed the phosphorylation of S6K1
induced either by WT or by a constitutively active Rheb mutant
(Fig. 4E). To exclude a role for the AMPK-raptor axis in
response to glucose depletion in TSC1-deficient cells, we mon-
itored the effect of the specific AMPK inhibitor compound C
on mTORC1 activity after glucose deprivation in TSC1-defi-
cient cells. We found that mTORC1 was still inhibited by
glucose depletion in AMPK inhibitor-treated TSC1-deficient
cells (Fig. 4F). We also found that the interaction between
GAPDH and Rheb was induced by glucose depletion in the
absence of TSC1 (Fig. 4C) and even in AMPK-inhibited TSC1-
deficient cells (Fig. 4F). This result suggests that the GAPDH-
Rheb interaction is regulated by glucose availability indepen-
dently of both the AMPK-TSC axis and the AMPK-raptor axis.
We also found that AMPK1-silenced HEK293 cells remain
responsive to glucose deprivation (Fig. 4G, lanes 5 and 6),
further supporting this idea. More importantly, the silencing of
both AMPK1 and GAPDH completely abolished mTORC1
signaling in response to glucose depletion (Fig. 4G, lanes 7 and
8). These results suggest that the GAPDH-Rheb axis consti-
tutes a new pathway that regulates mTORC1 in response to
glucose availability independently of the AMPK-TSC axis and
the AMPK-raptor axis.
GAPDH dissociates Rheb from mTORC1 under glucose-
depleted conditions. Having characterized the inhibitory effect
of GAPDH on mTORC1 signaling, we next sought to under-
stand how the interaction between GAPDH and Rheb regu-
lates mTORC1 signaling. Our results above showed that the
binding of Rheb to GAPDH is enhanced under low-glucose
conditions and that this correlates with the inhibition of
mTORC1 signaling. We therefore reasoned that the interac-
tion between GAPDH and Rheb somehow inhibits mTORC1’s
activity. We considered two possibilities for how this might
occur: GAPDH might bind mTORC1 via Rheb and inhibit
mTORC1 directly, or GAPDH could inhibit mTORC1 activity
indirectly by sequestering Rheb and preventing it from binding
to mTORC1. Our subsequent experiments supported this sec-
ond mechanism. First, we found that glucose depletion stabi-
lized the interaction between GAPDH and Rheb, whereas it
destabilized the interaction between Rheb and mTOR. We
confirmed these results by analyzing the interactions of both
endogenous and recombinant proteins (Fig. 5A and B). Sec-
ond, we could not detect GAPDH in mTORC1 immunopre-
cipitates, a result that excludes the first possibility (Fig. 5A,
lanes 1 and 2). Third, when Rheb was isolated from GAPDH-
depleted cells, more mTOR was found to be bound to it than
when Rheb was isolated from control siRNA-transfected cells
(Fig. 5C). These results suggest that GAPDH binds more ex-
tant Rheb under low-glucose conditions and thereby reduces
the amount of Rheb bound to mTOR.
To further confirm if the alteration in the interaction be-
tween Rheb and mTOR depends on the interaction between
GAPDH and Rheb, we incubated mTOR immunoprecipitates
with purified GAPDH in vitro. This led to a decrease in the
amount of Rheb bound to mTOR (Fig. 5D, compare lanes 1
and 2). Next, we included Gly-3-P, which is the metabolite
capable of destabilizing the GAPDH-Rheb interaction, in the
incubation. The addition of Gly-3-P increased the amount of
Rheb bound to mTOR (Fig. 5D, lanes 3 and 4). All of these
results are consistent with our observation that silencing
GAPDH increases the basal activity of mTORC1 (Fig. 4A and
B). Taken together, our results suggest that GAPDH nega-
FIG. 3. Gly-3-P, a glycolytic intermediate, destabilizes the Rheb-
GAPDH interaction. (A) Gly-3-P, a glycolytic intermediate that binds
GAPDH, inhibits Rheb-GAPDH interaction. GST-Rheb was incu-
bated with purified rabbit muscle GAPDH in the presence of the
indicated amounts of NAD, NADH, or Gly-3-P. (B) The Rheb-
GAPDH interaction is specifically inhibited by the glycolytic interme-
diate Gly-3-P. A 100 M concentration of glycolytic intermediates was
coincubated with purified rabbit muscle GAPDH and GST-Rheb in in
vitro binding assays. DHAP, dihydroxyacetone phosphate. (A and B)
After GST pulldown assays were performed, bound GAPDH was
analyzed by immunoblotting with anti-GAPDH antibodies (upper pan-
els). The amounts of GST-Rheb used were shown by Ponceau S stain-
ing (lower panels). (C) Glucose depletion-induced Rheb-GAPDH in-
teraction is restored by Gly-3-P. HEK293 cells were incubated with 5.5
mM glucose medium in the absence or presence of the indicated
concentrations of Gly-3-P for 30 min. Cell lysates were incubated with
Rheb antibodies. Immunoprecipitates were blotted with indicated an-
tibodies for GAPDH and Rheb. (D) Glucose depletion-induced Rheb-
GAPDH binding is recovered by Gly-3-P but not another metabolite,
3-PG. HEK293 cells transfected with HA-Rheb were incubated with
5.5 mM glucose medium in the presence of either Gly-3-P or 3-PG for
30 min. Cell lysates prepared from these cells were immunoprecipi-
tated with anti-HA antibodies. GAPDH bound to Rheb was analyzed
by anti-GAPDH immunoblotting. (C and D) Cells were treated with
glycolytic metabolites as previously described (34).
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tively regulates mTORC1 by preventing Rheb from associating
with mTOR under conditions of low glucose availability.
Inhibition of the Rheb-GAPDH interaction induces mTORC1
activation. To further explore the negative roles of the
GAPDH-Rheb interaction in mTORC1 signaling, we con-
structed Rheb truncation mutants (Fig. 6A) and analyzed the
ability of each of the fragments to bind GAPDH (Fig. 6B). We
identified a region of Rheb (residues 78 to 107) necessary for
GAPDH binding and named it GBR (GAPDH binding region)
(Fig. 6A to C). We next investigated whether GBR can inter-
fere with the binding of Rheb to GAPDH. Increasing the
amount of GBR inhibited the interaction between Rheb and
GAPDH in vitro (Fig. 6D). Given that the GBR fragment
interferes with the interaction between GAPDH and Rheb, we
FIG. 4. GAPDH has a negative effect on the mTORC1 activity. (A) GAPDH knockdown increases mTORC1 activity. HEK293 cells were
transfected with GAPDH_#1, GAPDH_#2, or luciferase siRNA and then cultured in 25 mM glucose medium for 48 h. Cell lysates were prepared
and analyzed by immunoblotting for the indicated proteins and phosphorylation states. (B) The negative effect of glucose depletion on mTORC1
activity is abolished in GAPDH-silenced cells. HEK293 cells expressing GAPDH_#1 or luciferase siRNA were incubated with media with the
indicated concentrations of glucose for 30 min. Two examples of S6K1 phosphorylation obtained from three independent experiments are shown.
The bar graph at the bottom shows the quantification of S6K1 phosphorylation. (C) mTORC1 signaling remains responsive to glucose depletion
in TSC1-deficient cells, and the Rheb-GAPDH interaction is increased under glucose depletion conditions. TSC1/ and TSC1/ MEFs were
incubated with media with the indicated concentrations of glucose for 30 min. The phosphorylation of endogenous S6K1 and 4EBP1 was
determined using phospho-specific antibodies for T389 and T37/46, respectively. The same cell lysates were immunoprecipitated with anti-Rheb
antibodies. Immunoprecipitates were blotted with the indicated antibodies for GAPDH and Rheb. The bar graph shows the quantification of S6K1
phosphorylation and GAPDH/Rheb ratios in immunoprecipitations from four different experiments. (D) TSC1/ and TSC1/ MEFs were
incubated with 25 mM 2DG for the indicated times. The phosphorylation of endogenous S6K1 and 4EBP1 was determined using phospho-specific
antibodies for T389 and T37/46, respectively. (E) Inhibition of glycolysis flux reduces the constitutively active mutant of Rheb-induced S6K1
phosphorylation. Cells transfected with either HA-Rheb WT or HA-Rheb CA were treated with 25 mM 2DG for 30 min. Two examples of
S6K1 phosphorylation obtained from three independent experiments are shown. The bar graph at the bottom shows the quantification of
S6K1 phosphorylation (, P  0.05). (F) The mTORC1 pathway was still responsive to glucose depletion under AMPK-inhibited conditions
in TSC1-deficient MEFs. TSC1/ MEFs were pretreated with the AMPK inhibitor (AMPKI) compound C (10 M) for 30 min and then
were incubated with media with the indicated concentration of glucose for 30 min. The phosphorylation of endogenous S6K1 was determined
using phospho-specific antibodies for T389. The same cell lysates were immunoprecipitated with anti-Rheb antibodies. Immunoprecipitates
were blotted with the indicated antibodies for GAPDH and Rheb. The bar graph shows the quantification of S6K1 phosphorylation and
GAPDH/Rheb ratios in immunoprecipitations from three different experiments. (G) mTORC1 signaling remains responsive to glucose
depletion in AMPK1-silenced cells, and silencing of both AMPK1 and GAPDH completely desensitizes mTORC1 signaling in response
to glucose depletion. HEK293 cells expressing GAPDH_#1, AMPK1, or luciferase siRNA were incubated with media with the indicated
concentrations of glucose for 30 min. The phosphorylation of endogenous S6K1 was determined using phospho-specific antibodies for T389.
The levels of expression of S6K1, GAPDH, and AMPK1 were analyzed using anti-S6K1, anti-GAPDH, and anti-AMPK antibodies. For
quantitation of total protein, we used equal amounts of the same cell lysates that were used for detecting phosphorylated proteins by Western
blotting separately. The bar graph shows the quantification of S6K1 phosphorylation from three different experiments.
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reasoned that GBR may enhance the interaction between
Rheb and mTOR. To test this, we constructed a GFP-tagged
GBR and confirmed that it binds to endogenous GAPDH by
comparing its binding with that of the whole Rheb protein
(Fig. 6E). We found that expression of GBR stabilized the
Rheb-mTOR interaction even under low-glucose conditions
(Fig. 6F, compare lanes 2 and 4). The stabilization of the
Rheb-mTOR interaction in cells expressing the GBR was ac-
companied by an increase in S6K1 phosphorylation. Further-
more, the cells expressing GBR exhibited a dose-dependent
increase in S6K1 phosphorylation even under low-glucose con-
ditions (Fig. 6G). This result further supports the idea that the
interaction between GAPDH and Rheb is inhibitory to
mTORC1 signaling.
DISCUSSION
In this study, we demonstrate that glycolysis is linked to the
mTORC1 pathway via the direct binding of GAPDH to Rheb.
The glycolytic flux regulates the interaction between GAPDH
and Rheb, and this interaction inhibits mTORC1 signaling by
preventing Rheb from binding to mTOR. We also found that
the inhibitory effect of GAPDH on mTORC1 was restored by
Gly-3-P, a glycolytic intermediate that binds GAPDH. Gly-3-P
destabilizes the interaction between GAPDH and Rheb, sug-
gesting that this glycolytic intermediate acts as a messenger to
regulate mTORC1 signaling in response to changes in the
glycolytic flux.
Although it is known that Rheb is necessary for the activa-
tion of mTOR, the exact regulatory function of Rheb has not
been clearly elucidated. Unlike other Ras GTPases that bind
their effectors only when they are charged with GTP, the GTP-
GDP status of Rheb does not alter its ability to bind mTOR
(30). In view of this atypical property of Rheb, it has been
speculated that an unidentified factor may regulate the binding
of Rheb to mTOR (3). In our study, we found that GAPDH
regulates the binding of Rheb to mTOR in a manner that is
dependent upon glucose levels and independent of the nucle-
otide-charged status of Rheb (Fig. 2). To our knowledge, this
constitutes the first evidence that GAPDH regulates mTORC1
activity by binding Rheb and thereby modulating its interaction
with mTOR.
Although GAPDH is known as a glycolytic enzyme, recent
studies have shown that it may be involved in diverse cellular
processes, including membrane fusion, microtubule bundling,
nuclear RNA export, DNA repair, transcriptional regulation,
FIG. 5. GAPDH causes Rheb to dissociate from mTORC1 under low-glucose conditions. (A) Coimmunoprecipitation of endogenous proteins.
HEK293 cells were incubated with media with the indicated concentrations of glucose for 30 min and then immunoprecipitated with either
anti-mTOR (lanes 1 and 2) or anti-Rheb (lanes 3 and 4) antibodies. Immunoprecipitates were blotted with the indicated antibodies for mTOR,
raptor, Rheb, GAPDH, pS6K1, and S6K1. (B) Glucose depletion-induced Rheb-GAPDH binding reduces Rheb-mTOR association. HEK293 cells
transfected with HA-Rheb were incubated in 5.5 mM glucose medium for 30 min and then incubated with 25 mM glucose medium for the indicated
times. Cell lysates were immunoprecipitated with anti-HA antibodies and then immunoblotted with anti-mTOR and anti-GAPDH antibodies.
(C) GAPDH knockdown increases Rheb-mTOR association. HEK293 cells were transfected with GAPDH_#1 or luciferase siRNA. Cell lysates
were immunoprecipitated with Rheb antibodies. Immunoprecipitates were blotted with the indicated antibodies for mTOR, GAPDH, and Rheb.
(D) GAPDH inhibits the association between Rheb and mTORC1 in vitro. The Myc-tagged mTOR immunocomplexes were prepared from
HEK293 cells and incubated with soluble GST-Rheb in the presence or absence of purified rabbit muscle GAPDH, with or without Gly-3-P.
GST-Rheb bound to the mTOR complex was analyzed by anti-Rheb immunoblotting. Amounts of Myc-mTOR immunocomplexes used are shown
by anti-mTOR immunoblotting.
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and apoptosis (9, 24, 41). Our findings further extend the
multifunctional character of GAPDH. Although the Rheb-
GAPDH interaction increases when the glycolytic flux is re-
duced, the interaction was still detected even under high-glu-
cose conditions (Fig. 2). This implies that GAPDH shuttles
between the glycolysis pathway and the mTORC1 pathway to
facilitate the immediate response of mTORC1 signaling to the
glycolytic flux (Fig. 7).
The glycolytic pathway is regulated in an allosteric manner
by phosphofructokinase 1 (PFK-1), which functions to regulate
the flow of glycolysis (26). The enzymatic activity of PFK-1 is
regulated by the end product of glycolysis such as ATP. For
this reason, the increased production of a glycolytic interme-
diate (such as fructose 6-phosphate) by upstream enzymes in
the glycolytic pathway would not increase the glycolytic flux via
PFK-1. On the other hand, the GAPDH-mediated reaction is
substrate limited and determined by the instantaneous concen-
tration of the substrate (26). Whereas PFK-1 is likely regulated
by both the net glycolytic flux and the nonglycolytic processes
that affect cellular ATP levels, GAPDH is likely to be entirely
controlled by the influx of glucose. Therefore, we hypothesize
that GAPDH is better suited than other enzymes in the glyco-
lytic pathway to monitor the glycolytic flux that depends on the
supply of extracellular glucose.
Previously, it was suggested that a link exists between AMPK
and the mTORC1 pathway under conditions of energy star-
vation (22). In that study, treatment with 2DG or glucose
starvation resulted in decreased cellular ATP levels and the
subsequent activation of AMPK. AMPK was proposed to
stimulate TSC2 to serve as a GTPase-activating protein for
FIG. 6. Blocking of the Rheb-GAPDH interaction increases the mTORC1 activity. (A and B) Identification of the GAPDH binding region in
Rheb. Considering the secondary structure elements of Rheb (48), we generated GST-tagged serial deletion mutants of Rheb (	C1 to 	C4). The
recovery of GST-Rheb constructs with GAPDH is indicated on the left of panel A as  or , and the immunoblot data supporting this summary
are shown in panel B. (C) GAPDH specifically interacts with the Rheb (78–107) fragment in vitro. GST-tagged Rheb fragment 78 to 107
(GST-GBR) was incubated with purified rabbit muscle GAPDH. Bound GAPDH was analyzed by immunoblotting with anti-GAPDH antibodies
(upper panel), and the amounts of GST or GST-GBR used were shown by Ponceau S staining (lower panel). (D) GST-GBR disrupts the
interaction between GAPDH and full-length Rheb. For in vitro competition assays using GST-tagged GBR, GAPDH was mixed with immobilized
His-tagged full-length Rheb on Ni-NTA agarose. Purified GST-GBR was then added in increasing amounts (0, 1, and 5 g) and incubated for 2 h
at 4°C. GAPDH remaining on the Ni-NTA agarose was analyzed by anti-GAPDH immunoblotting. The 1/25 input of the samples was immuno-
blotted using anti-Rheb antibodies to determine the relative amounts of His-Rheb and GST-GBR used. (E) GFP-tagged GBR specifically interacts
with endogenous GAPDH. (Top panels) Schematic representation of GFP-tagged Rheb constructs. (Bottom panels) HEK293 cells transfected
with GFP-tagged Rheb WT or GFP-tagged GBR were subjected to coimmunoprecipitation with anti-GFP antibodies. Immunoprecipitates were
blotted with anti-GAPDH antibodies for GAPDH and with anti-GFP antibodies for GFP-tagged proteins. (F) Overexpression of GBR induces
both the Rheb-mTOR interaction and the hyperactivation of mTORC1. HEK293 cells transfected with either enhanced GFP or enhanced
GFP-tagged GBR were incubated with media with the indicated concentrations of glucose for 30 min. Cell lysates were immunoprecipitated with
Rheb antibodies. Immunoprecipitates and cell lysates were blotted with the indicated antibodies. Representative results of immunoblotting from
three independent experiments are shown. (G) HEK293 cells transfected with incremental doses (0, 0.2, and 2 g) of enhanced GFP-tagged GBR
were incubated in 5.5 mM glucose medium for 30 min. The phosphorylation of S6K1 was determined by immunoblotting. The bar graph at the
bottom shows the increase in phosphorylation of S6K1 over that of the control. For quantitation of total protein, we used equal amounts of the
same cell lysates that were used for detecting phosphorylated proteins by Western blotting separately.
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Rheb and thereby inhibit the mTORC1 pathway under condi-
tions of glucose starvation. A recent report showed that acti-
vated AMPK regulates mTORC1 signaling not only through
TSC1-TSC2 but also through direct phosphorylation of raptor
(14). In our study, we found a new pathway in which the
glycolytic enzyme GAPDH directly binds to Rheb and thereby
inhibits mTORC1 signaling in response to glucose availability
independently of the AMPK-TSC axis and the AMPK-raptor
axis. Interestingly, we found that the GAPDH-Rheb interac-
tion is dramatically increased in TSC1-deficient MEFs and
AMPK-inhibited TSC1-deficient MEFs, even under high-glu-
cose conditions (Fig. 4C and F). An increase in the GAPDH-
Rheb interaction was also observed in AMPK1-silenced
HEK293 cells (data not shown). Although both the absence of
TSC1 and the inhibition of AMPK activity increased basal
GAPDH-Rheb interaction, the GAPDH-Rheb interaction was
still responsive to glucose (Fig. 4C and F). However, at this
time, it is unclear whether AMPK activity directly regulates
the GAPDH-Rheb interaction. Interestingly, we observed that
AMPK activity is significantly elevated in TSC1-deficient MEFs
relative to WT MEFs (data not shown). We presume that
TSC1-deficient cells have a highly activated mTORC1 pathway
and thus consume much cellular energy to support cell growth.
This idea is supported by the increased levels of both AMPK
and ACC phosphorylation in these cells. One might expect this
to result in energy depletion and eventual energy crisis-medi-
ated cell death. However, we did not observe any kind of cell
death in TSC1-deficient cells. Possibly, TSC1-deficient cells do
not undergo energy starvation-induced apoptosis because they
lack p53, as suggested in a previous model (25a ). We observed
that the GAPDH-Rheb interaction is dramatically enhanced in
TSC1-deficient MEFs and that this interaction is regulated by
glucose availability in both TSC1-deficient MEFs and AMPK-
inhibited cells. We hypothesize that the GAPDH-Rheb inter-
action may act as a cellular safety device to prevent uncon-
trolled mTOR activation and energy crisis-mediated cell death
under abnormal cellular circumstances, such as TSC deficiency
and/or loss of AMPK function. Further study would be needed
to confirm such a protective role for GAPDH. Relevant ques-
tions would include whether the GAPDH-Rheb interaction is
elevated in TSC patient tissue or when AMPK function is lost
and whether the silencing of GAPDH severely induces energy
crisis-mediated cell death under these circumstances.
Taken together, mTORC1 inhibition under low-glucose con-
ditions seems to occur as a result of multiple pathways: (i) the
AMPK-TSC axis, (ii) the AMPK-raptor axis, and (iii) the
GAPDH-Rheb axis. Cells may have developed these multiple
ways of regulating mTORC1 signaling in response to glucose
levels to deal with a wider diversity of energy and stress con-
ditions. In this light, it is important that the two AMPK-regu-
lated pathways depend on the AMP/ATP ratio. Therefore,
these pathways will respond not only to glucose-deprived con-
ditions but also to many other stress conditions that reduce
ATP levels. In contrast, the GAPDH-Rheb pathway is more
directly linked to glucose metabolism. Thus, the GAPDH-
Rheb axis may be responsible for more intimate cross talk
between the glycolytic pathway and the mTORC1 pathway,
and the AMPK-dependent pathways may be responsive to
other cellular energy states and/or stress conditions that alter
the AMP/ATP ratio. Further studies are needed to address the
relative contributions of the three pathways to the regulation
of mTORC1 in response to glucose availability. From an evo-
FIG. 7. Model for the regulation of mTORC1 signaling in response to glycolytic flux via GAPDH-Rheb interaction. GAPDH acts as a
glycolytic messenger that senses the glycolytic flow and signals to the mTORC1 pathway by interacting with Rheb. The extracellular glucose
sufficiency increases the intracellular glycolytic flux, resulting in the accumulation of Gly-3-P and GAPDH charged with Gly-3-P, the form
that is incapable of binding Rheb. Under low-glucose conditions, a decrease in the supply of extracellular glucose may result in the
accumulation of GAPDH uncharged with Gly-3-P, which prevents Rheb from binding to mTORC1 and thereby inhibits mTORC1 signaling.
TCA, tricarboxylic acid.
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lutionary point of view, whether GAPDH is involved in the
regulation of TORC1 in yeast will also be an interesting ques-
tion. Given that the GAPDH-Rheb axis can inhibit mTORC1
signaling even when there is a TSC1 deficiency or Rheb is
constitutively active, our study provides important insight into
the development of therapeutic approaches to human diseases
caused by defects in TSC.
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